New drug combo aims to protect heart during chemo

NCT ID NCT06815575

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This early-stage study tests a new drug called RC220 given with a standard chemotherapy (doxorubicin) in adults with advanced solid tumors. The goal is to find a safe dose and see if RC220 can protect the heart from doxorubicin's side effects. About 53 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Care Foundation

    RECRUITING

    Miranda, New South Wales, 2228, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gosford Hospital

    RECRUITING

    Gosford, New South Wales, 2250, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Prince of Wales Hospital

    RECRUITING

    Shatin, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Queen Mary Hospital

    RECRUITING

    Hong Kong, 999077, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Wyong Hospital

    RECRUITING

    Wyong, New South Wales, 2259, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.